Cresilon
Cresilon is a Brooklyn-based medical device company that develops and manufactures proprietary plant-based hemostatic gel products — TRAUMAGEL for human trauma care and VETIGEL for veterinary surgery — distributed through authorized medical distributors, channel partners, and GPOs to EMS agencies, trauma hospitals, military, and veterinary clinics worldwide.
- Company typePrivate
- Founded2010
- HeadquartersBrooklyn, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cresilon does
Cresilon is a Brooklyn-based biotechnology company founded in 2010 by Joe Landolina and Isaac Miller that develops and manufactures proprietary plant-based hemostatic gel products for both human trauma care and veterinary surgical applications. Its core technology is a hydrogel composed of refined algal polysaccharides that forms a mechanical barrier at wound sites, achieving hemostasis in seconds without preparation, manual pressure, or animal-derived components. The product portfolio comprises three FDA-cleared or in-commercialization brands built on a single platform: Cresilon Hemostatic Gel (CHG), cleared in June 2023 for minor cuts and abrasions; TRAUMAGEL, a 30 mL pre-filled syringe FDA 510(k) cleared in August 2024 (K233762) for temporary external control of moderate to severe bleeding; and VETIGEL, a 5 mL veterinary hemostatic gel launched in 2020 and used in over 65,000 procedures worldwide. Cresilon holds ISO 13485:2016 certification and operates a 55,000 sq ft GMP-certified biomanufacturing facility in Brooklyn's Industry City — the only GMP-certified biotech manufacturer in all five boroughs of New York City — with annual production capacity of approximately 300,000 syringes.
The company's revenue model is hardware product sales through a multi-channel distribution network. TRAUMAGEL sells exclusively through authorized medical distributors (Pacific Biomedical, Life-Assist, Bound Tree, Henry Schein, ADS Inc.) to EMS agencies, fire departments, Level 1 trauma centers, and military medical units, with a Vizient GPO Innovative Technology contract awarded in March 2026 expanding hospital access. VETIGEL distributes exclusively through Zomedica in the U.S. (under a license-and-supply agreement signed January 2025) and through Covetrus in Europe/UK, McCarthy Vet in Canada, and VerticalVet's 1,800 GPO clinics. Pricing is quote-based and not publicly disclosed. The company has raised over $100 million in cumulative funding across Series A rounds, including a $38.5M Series A-3 (September 2021) and a $25M Series A-4 led by Paulson Investment Company (October 2022), plus a $17M growth round in 2025. Revenue is not publicly disclosed. End customers include Cobb County Fire & EMS, Orangeburg County EMS, Level 1 trauma centers in Denver, Louisiana State University Health Science Center, and veterinary surgical practices across North America, Europe, and Japan.
Cresilon firmographics
Firmographics- Name
- Cresilon
- Legal name
- Cresilon, Inc.
- Website
- https://cresilon.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cresilon is a Brooklyn-based medical device company that develops and manufactures proprietary plant-based hemostatic gel products — TRAUMAGEL for human trauma care and VETIGEL for veterinary surgery — distributed through authorized medical distributors, channel partners, and GPOs to EMS agencies, trauma hospitals, military, and veterinary clinics worldwide.
- Ownership category
- akta.pro rank
Cresilon industry classification
Industry- Product category
- Hemostatic Medical Devices
- NAICS
- Adhesive Manufacturing (325520)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
- akta.pro secondary industry
- Practice Consumables & General Medical Supplies (Needles, Syringes, Gloves, Swabs) (HLAMAFAO)
Keywords
Where Cresilon is headquartered
LocationHeadquarters
- HQ city
- Brooklyn
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cresilon business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- VETIGEL Product Sales: Direct product sales of VETIGEL hemostatic gel to veterinary surgeons and clinics through distribution partners including Zomedica (exclusive U.S.), McCarthy Vet (Canada), Covetrus (Europe/UK), and VerticalVet (GPO). Supplied in pre-filled 5mL syringes.
- TRAUMAGEL Product Sales: Sales of TRAUMAGEL to EMS agencies, first responders, emergency departments, and trauma centers through authorized distributors. Supplied in sterile 30mL pre-filled syringes. Products available through Pacific Biomedical, Life-Assist, Bound Tree, Henry Schein, and ADS, Inc.
- Licensing & Supply Agreement with Zomedica: Zomedica has exclusive license to market and sell VETIGEL in the U.S. and non-exclusive license internationally. Cresilon supplies product to Zomedica for distribution to U.S. customers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | TRAUMAGEL 30mL Syringe - Quote-based pricing through distributors |
| Unit Pricing | Pay-as-you-go | VETIGEL 5mL Syringe - Quote-based pricing through distributors |
Go-to-market motion3 records
Distribution channels10 records
Marketing channels6 records
Cresilon product offering
Product offeringCore offering
Cresilon develops and manufactures proprietary plant-based hemostatic gel products that stop external bleeding in seconds. The portfolio includes TRAUMAGEL (30 mL pre-filled syringe, FDA 510(k) cleared for moderate-to-severe bleeding in EMS, trauma hospitals, military and law enforcement), VETIGEL (5 mL pre-filled syringe for veterinary surgical hemostasis), and Cresilon Hemostatic Gel (CHG) for minor cuts, lacerations and abrasions. All products leverage the same proprietary biopolymer hydrogel platform and are produced at the company's GMP-certified Brooklyn, NY biomanufacturing facility.
Product overview
Cresilon develops and manufactures proprietary plant-based hemostatic gel technology that stops bleeding in seconds. The product portfolio consists of two main brands: TRAUMAGEL for human trauma care (FDA 510(k) cleared for temporary external use to control moderate to severe bleeding) delivered in 30 mL syringes, and VETIGEL for veterinary applications delivered in 5 mL syringes. A third product, Cresilon Hemostatic Gel (CHG), received FDA clearance in 2023 for minor wound care. All products utilize the same proprietary hydrogel technology platform but are differentiated by indication, dosage, and regulatory clearance status.
Differentiator
Problem solved
Functional benefit
Brands
- TRAUMAGEL: Hemostatic gel for temporary external use to control moderate to severe bleeding in humans. FDA 510(k) cleared for EMS, trauma hospitals, military, and law enforcement.
- VETIGEL
- Cresilon Hemostatic Gel (CHG)
Products and services
- TRAUMAGEL TRAUMAGEL is a hemostatic gel supplied in a sterile individually pouched 30 mL pre-filled syringe. It is FDA 510(k) cleared for temporary external use to control moderate to severe bleeding, requires no preparation, and achieves hemostasis in seconds by forming a mechanical barrier at the wound site. It is sold to licensed healthcare providers via authorized U.S. medical distributors.
- VETIGEL VETIGEL is Cresilon's first hemostatic gel in the veterinary market, supplied in a 5 mL pre-filled syringe and made from plant-based polymers. It is designed to stop bleeding in seconds for veterinary surgical procedures and has been used in over 65,000 veterinary procedures worldwide. It is sold via Zomedica (exclusive U.S.), McCarthy Vet (Canada), Covetrus (Europe/UK) and the VerticalVet GPO.
- Cresilon Hemostatic Gel (CHG) Cresilon Hemostatic Gel (CHG) is Cresilon's first FDA-cleared hemostatic gel for human use, indicated for the local management of bleeding wounds such as minor cuts, lacerations, and abrasions. It leverages the same proprietary plant-based hydrogel technology platform as TRAUMAGEL and VETIGEL.
Quantifiable outcome
- Saves at least one life per day on average across U.S. deployment
- +4 more outcomes
Companies that use Cresilon
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles5 records
Cresilon technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cresilon partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and flagship.
- VizientcoreInnovative Technology contract awarded to TRAUMAGEL based on expert reviews from hospital experts serving on Vizient's client-led councils. Vizient is the nation's largest provider-driven healthcare performance improvement company representing over $156 billion in annual purchasing volume.
- McCarthy VetcoreMcCarthy Vet is Cresilon's first veterinary distribution partner in Canada. McCarthy Vet, a family-owned company serving Canadian veterinarians for over 60 years, distributes VETIGEL directly to veterinary surgeons in Canada.
- ZomedicaflagshipZomedica has exclusive license to market and sell VETIGEL hemostatic gel in the U.S. and non-exclusive license internationally. Cresilon supplies product to Zomedica for distribution to U.S. customers through Zomedica's established field sales team and trade programs.
- VerticalVetcorePreferred Partnership Agreement providing VerticalVet's 1,800 GPO member veterinary clinics access to VETIGEL. VerticalVet is a Group Resource Community offering customized education, data insights, and tailored partner solutions.
- CovetruscoreInternational distribution agreement for VETIGEL making the product available in Europe and the UK through Covetrus's distribution network.
- Walter Reed Army Institute of Research (WRAIR)coreCooperative Research and Development Agreement (CRADA) to study Cresilon's hemostatic gel technology as a potential field and prehospital treatment for penetrating traumatic brain injury (TBI). First phase preclinical study demonstrated promising safety and efficacy results.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Cresilon competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Cresilon social profiles
Digital presenceCresilon compliance and trust
Trust signalCompliance3 records
Cresilon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cresilon leadership team
Management profileNumber of profiles
Profiles13 records
Cresilon funding detail
Funding detailFunding overview
Funding rounds8 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cresilon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cresilon
What does Cresilon do?
Cresilon develops and manufactures proprietary plant-based hemostatic gel products that stop external bleeding in seconds. The portfolio includes TRAUMAGEL (30 mL pre-filled syringe, FDA 510(k) cleared for moderate-to-severe bleeding in EMS, trauma hospitals, military and law enforcement), VETIGEL (5 mL pre-filled syringe for veterinary surgical hemostasis), and Cresilon Hemostatic Gel (CHG) for minor cuts, lacerations and abrasions. All products leverage the same proprietary biopolymer hydrogel platform and are produced at the company's GMP-certified Brooklyn, NY biomanufacturing facility.
Is Cresilon a public or private company?
Cresilon is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cresilon founded?
Cresilon was founded in 2010. It employs 101 to 250 people.
Where is Cresilon based?
Cresilon is headquartered in Brooklyn, United States, in the North America region.
How does Cresilon make money?
Three revenue lines are on record. VETIGEL Product Sales are the primary driver. The others are TRAUMAGEL Product Sales and licensing & Supply Agreement with Zomedica.
Does Cresilon have an API?
No public API is recorded for Cresilon.
What industry is Cresilon in?
Cresilon's product category is Hemostatic Medical Devices. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAMAFAO, Practice Consumables & General Medical Supplies (Needles, Syringes, Gloves, Swabs). Its NAICS code is 325520 and its SIC code is 3841.